source
- Biopharma must incentivize scientists to make early go-no-go decisionsThe article argues that simply urging scientists to think like entrepreneurs is not enough; biopharma firms need to align rewards with that mindset. Because only about one in ten drug candidates t…
- Biopharma needs to reward scientists' judgmentIt’s not enough for organizations to want scientists to think like entrepreneurs. They have to incentivize and reward for that behavior.BioSpace · 22d ago↗ source
- AstraZeneca invests $2 billion in Summit Therapeutics to advance PD-1xVEGF bispecific ivonescimab with ADC combosAstraZeneca is committing $2 billion to Summit Therapeutics, acquiring a 12% equity stake at a premium to the biotech's closing price. The funding is aimed at accelerating development of the PD‑1xV…